Fig. 1

CARHSP1 is upregulated and associated with a worse prognosis in PCa. (A) CARHSP1 expression in various cancers and corresponding normal tissues from the UALCAN cancer database. Red column, cancer tissues; blue column, normal tissues. (B) CARHSP1 transcript levels in paired normal prostate tissues (n = 29) and prostate cancer tissues (n = 29) from GEO (GSE21034) databases. (C) Violin plots demonstrating CARHSP1 mRNA overexpression in PCa primary/malignant tissues compared to normal/benign tissues in four independent datasets. (D) CARHSP1 mRNA expression in prostate cancer tissues with different Gleason score and diseases stage (T-stage). Data were extracted from TCGA and GEO PCa datasets. (E) Western blotting analysis of CARHSP1 protein expression levels in human prostate cancer cell lines (C4-2, 22Rv1, PC-3, DU145, and LNCaP cells) and the normal prostate cell lines (RWPE-1, P69). β-actin was used as the internal loading control. (F) Analysis of CARHSP1 mutation and copy-number alterations frequency across 7 PCa genomic datasets in cBioportal website. (G, H) Association between progression-free survival (PFS)/disease-free interval (DFI) of prostate cancer patients and CARHSP1 mRNA expression from the GSCA PCa database. (I) Association between DFI of prostate cancer patients and CARHSP1 copy number variation from the GSCA PCa database. (J) CARHSP1 expression in primary and recurrent PCa tissues from TCGA database. *p < 0.05; **p < 0.01; ***p < 0.001; ns, not significant